We are live on
!
Find out more
RAM
RK Asset Management Portfolio holdings
AUM
$106M
1-Year Est. Return
0.38%
This Fund
S&P 500
This Quarter
Est. Return
+1.05%
1 Year Est. Return
-0.38%
3 Year Est. Return
+47.65%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$122M
AUM Growth
-$7.75M
(-6%)
Cap. Flow
-$3.58M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
59.63%
Holding
23
New
–
Increased
1
Reduced
21
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$752K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fastenal
FAST
|
+$707K |
| 2 |
Buckle
BKE
|
+$553K |
| 3 |
Allegiant Air
ALGT
|
+$410K |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$309K |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$269K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 25.23% |
| 2 | Consumer Discretionary | 21.41% |
| 3 | Financials | 17.33% |
| 4 | Industrials | 16.48% |
| 5 | Healthcare | 9.79% |
Similar funds
KCM
SM
AFA
SHWA
TAI
MPGIG
EPW
SFG
RK Asset Management's Q4 2024 Portfolio in Review
As of Q4 2024, RK Asset Management held 23 positions worth $122M, down 6% from $130M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 0%. RK Asset Management opened no new positions and made no exits, leaving the 23-position portfolio largely intact.
By sector, the portfolio is most concentrated in Consumer Staples at 25% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Financials.
- RK Asset Management added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $752K increase.
- RK Asset Management's biggest Q4 2024 reduction was Fastenal, cutting an estimated $707K.
- RK Asset Management's ten largest holdings make up 60% of its $122M portfolio in Q4 2024.
- RK Asset Management opened 0 new positions and closed 0 in Q4 2024.
- RK Asset Management's portfolio value fell 6% quarter-over-quarter to $122M.
Based on RK Asset Management's 13F filing for Q4 2024, filed 3 Jan 2025.